Accurate intraoperative identification of glioma molecular subtypes, such as isocitrate dehydrogenase mutation and 1p/19q co-deletion, is essential for precise diagnosis, prognostication, and determining the extent of tumor resection—balancing maximal tumor removal with preservation of neurological function. This evidence concerns the gene IDH3A and central nervous system cancer.